Tilray Brands, Inc. Common Stock (TLRY) — Analysis Summary
Tilray Brands, Inc. Common Stock (TLRY) has a market cap of $550.62M with year-over-year revenue growth of +4.1%. Net margin stands at -266.3%. The stock trades at a P/E ratio of -0.4.
Key Takeaways
- Revenue changed +4.1% year-over-year
- Net margin of -266.3%
- P/E ratio of -0.4
Compared to other companies in the MEDICINAL CHEMICALS & BOTANICAL PRODUCTS sector, TLRY posted revenue growth of +4.1% and trades at a P/E of -0.4.
Tilray Brands, Inc. Common Stock (TLRY)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -36.1x — earnings do not cover interest payments
Operating margin at -173.7% — severe operating losses
Net margin at -156.7% — losses exceed revenue (possible one-time charges)
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
Sector
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Employees
2,842
Headquarters
NEW YORK, NY
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.